Search research articles
Contact Us
Filters
Showing results (171-180 of 205) with videos related to
Page
of 21
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 31, 2013
Prevalence and co-occurrence of actionable genomic alterations in high-grade bladder cancer
Gopa Iyer, Hikmat Al-Ahmadie, Nikolaus Schultz, et al.
European Urology
|
October 20, 2023
European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2023 Guidelines
J Alfred Witjes, Harman Max Bruins, Albert Carrión, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 10, 2020
Randomized Double-Blind Phase II Study of Maintenance Pembrolizumab Versus Placebo After First-Line Chemotherapy in Patients With Metastatic Urothelial Cancer
Matthew D Galsky, Amir Mortazavi, Matthew I Milowsky, et al.
Cancer
|
August 9, 2020
A phase 2 trial of buparlisib in patients with platinum-resistant metastatic urothelial carcinoma
Victor McPherson, Brendan Reardon, Aravind Bhayankara, et al.
Nature Medicine
|
February 27, 2026
A small-molecule inverse agonist of PPARγ for advanced solid tumors: a phase 1 trial
Matthew D Galsky, Charlene Mantia, Michaela Bowden, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 12, 2021
Identification of a Novel Inflamed Tumor Microenvironment Signature as a Predictive Biomarker of Bacillus Calmette-Guérin Immunotherapy in Non-Muscle-Invasive Bladder Cancer
Jeffrey S Damrauer, Kyle R Roell, Markia A Smith, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 12, 2024
Patient-Reported Outcomes in Patients With Advanced Urothelial Cancer Who Are Ineligible for Cisplatin and Treated With First-Line Enfortumab Vedotin Alone or With Pembrolizumab
Matthew I Milowsky, Peter H O'Donnell, Christopher J Hoimes, et al.
European Urology
|
March 16, 2024
Corrigendum to "European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2023 Guidelines" [Eur. Urol. 85 (2024) 17-31]
J Alfred Witjes, Harman Max Bruins, Albert Carrión, et al.
Cancer
|
August 7, 2020
A randomized phase 2 trial of pembrolizumab versus pembrolizumab and acalabrutinib in patients with platinum-resistant metastatic urothelial cancer
Tian Zhang, Michael R Harrison, Peter H O'Donnell, et al.
European Urology Oncology
|
December 17, 2023
A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients with Advanced or Metastatic Urothelial Carcinoma
Pavlos Msaouel, Randy F Sweis, Manojkumar Bupathi, et al.
Page
of 21
Search research articles
Search
Showing results (171-180 of 205) with videos related to
Sort By:
Page
of 21
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 31, 2013
Prevalence and co-occurrence of actionable genomic alterations in high-grade bladder cancer
Gopa Iyer, Hikmat Al-Ahmadie, Nikolaus Schultz, et al.
European Urology
|
October 20, 2023
European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2023 Guidelines
J Alfred Witjes, Harman Max Bruins, Albert Carrión, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 10, 2020
Randomized Double-Blind Phase II Study of Maintenance Pembrolizumab Versus Placebo After First-Line Chemotherapy in Patients With Metastatic Urothelial Cancer
Matthew D Galsky, Amir Mortazavi, Matthew I Milowsky, et al.
Cancer
|
August 9, 2020
A phase 2 trial of buparlisib in patients with platinum-resistant metastatic urothelial carcinoma
Victor McPherson, Brendan Reardon, Aravind Bhayankara, et al.
Nature Medicine
|
February 27, 2026
A small-molecule inverse agonist of PPARγ for advanced solid tumors: a phase 1 trial
Matthew D Galsky, Charlene Mantia, Michaela Bowden, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 12, 2021
Identification of a Novel Inflamed Tumor Microenvironment Signature as a Predictive Biomarker of Bacillus Calmette-Guérin Immunotherapy in Non-Muscle-Invasive Bladder Cancer
Jeffrey S Damrauer, Kyle R Roell, Markia A Smith, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 12, 2024
Patient-Reported Outcomes in Patients With Advanced Urothelial Cancer Who Are Ineligible for Cisplatin and Treated With First-Line Enfortumab Vedotin Alone or With Pembrolizumab
Matthew I Milowsky, Peter H O'Donnell, Christopher J Hoimes, et al.
European Urology
|
March 16, 2024
Corrigendum to "European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2023 Guidelines" [Eur. Urol. 85 (2024) 17-31]
J Alfred Witjes, Harman Max Bruins, Albert Carrión, et al.
Cancer
|
August 7, 2020
A randomized phase 2 trial of pembrolizumab versus pembrolizumab and acalabrutinib in patients with platinum-resistant metastatic urothelial cancer
Tian Zhang, Michael R Harrison, Peter H O'Donnell, et al.
European Urology Oncology
|
December 17, 2023
A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients with Advanced or Metastatic Urothelial Carcinoma
Pavlos Msaouel, Randy F Sweis, Manojkumar Bupathi, et al.
Page
of 21